Executive Functioning in TBI From Rehabilitation to Social Reintegration: COMPASS (COMPASS)
|ClinicalTrials.gov Identifier: NCT01816061|
Recruitment Status : Active, not recruiting
First Posted : March 21, 2013
Last Update Posted : October 30, 2017
|Condition or disease||Intervention/treatment|
|Traumatic Brain Injury Post-Traumatic Stress Disorder||Behavioral: Experimental - COMPASS Behavioral: Control - COMPASS|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||110 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Executive Functioning in TBI From Rehabilitation to Social Reintegration: COMPASS|
|Actual Study Start Date :||March 12, 2014|
|Primary Completion Date :||March 6, 2017|
|Estimated Study Completion Date :||March 31, 2018|
Experimental: Arm 1: Experimental
The COMPASS (Community Participation through Self-Efficacy Skills Development) program aims at developing and testing a novel patient-centered intervention framework that can be utilized as a platform for VA community re-integration comparative effectiveness research.
Behavioral: Experimental - COMPASS
Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
Active Comparator: Arm 1: Control
Fifty-five participants in the supported discharge, or control, group will not receive the intervention, but will receive phone calls to answer a short questionnaire and check in on their status.
Behavioral: Control - COMPASS
Increased hours of patient-provider interactions Group.
Other Name: Supported discharge group
- Change from Baseline in Community Reintegration for Injured Service Members at 2 months [ Time Frame: 2 months ]Measured through Community Reintegration for Injured Service Members (CRIS)
- Change from Baseline in Frontal Systems Behavior Scale at 2 months [ Time Frame: 2 months ]Measured through Frontal Systems Behavior Scale (FrSBe)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01816061
|United States, District of Columbia|
|Washington DC VA Medical Center, Washington, DC|
|Washington, D.C., District of Columbia, United States, 20422|
|Principal Investigator:||Alexander V Libin, PhD||Washington DC VA Medical Center, Washington, DC|